The minimally invasive soft channel brain hemorrhage evacuation for acute basal ganglia hemorrhage - small hemorrhage evacuation (MIRACLE-S) trial: rationale, design and progress
Cerebrovascular Diseases · 14.11.2026
DOI: 10.1159/ced/accag012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cerebrovascular Diseases, online erschienen am 14.11.2026. Verfasst von Xia Wang und 19 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Acute spontaneous intracerebral hemorrhage (ICH) is a devastating type of stroke, where patients with small and large hematomas usually make excellent and poor outcomes, respectively, regardless of treatment. However, for patients with a moderate hematoma volume (20–30 mL) in a deep hemispheric location, there is clinical equipoise as to the benefit of any surgical intervention, as the randomized evidence is limited.
Methods
The minimally invasive soft-channel brain hemorrhage evacuation for acute basal ganglia hemorrhage – small hemorrhage evacuation (MIRACLE-S) trial is a multicenter, prospective, randomized, open-label, blinded-endpoint assessed trial conducted in China. Eligibility criteria are adult patients aged 18 to 80 years with spontaneous basal ganglionic ICH with a hematoma volume of 20 to 30 mL, Glasgow coma scale score 9 to 14, premorbid modified Rankin scale score 0 to 1, and systolic blood pressure <140 mmHg enrolled within 48 hours of symptom onset. Patients are randomized (1:1) to soft-channel minimally invasive surgery (scMIS; stereotactic aspiration with catheter-based urokinase thrombolysis) or guideline-based conservative medical management. The primary efficacy outcome is a hierarchical composite endpoint of death, disability (mRS scores 3 to 5), rehospitalization, and poor health-related quality of life assessed at 180 days and analyzed using a win-ratio approach. Safety outcomes include mortality, rebleeding (including puncture-tract hemorrhage), and infection within 30 days.
Results
Recruitment started January 1, 2025. As of January 10, 2026, 148 patients have been randomized at 34 active sites. The required sample size of 420 to detect a win-ratio effect size of 1.62 (P_tie=0.05) should be achieved in 2028.
Conclusion
MIRACLE-S will clarify whether aspiration-based scMIS improves recovery as compared with best medical management in patients moderate-volume basal ganglionic ICH, which is a common clinical burden in China and other regions with high rates of ICH.
Trial registration
ClinicalTrials.gov Identifier: NCT06688162.
Autor:innen und Institutionen
ORCID-Profile: Craig Anderson, Xunming Ji
Zitieren
APA
Wang, X., Zeng, J. F., Luo, L., Bian, H., Liu, Z., Xie, Z., Li, B., Zhao, F., He, F., Song, X., Chen, X., Li, S., Huang, C., Du, C., Wang, Q., Song, L., Anderson, C., Che, F., Xin, T., & Ji, X. (2026). The minimally invasive soft channel brain hemorrhage evacuation for acute basal ganglia hemorrhage - small hemorrhage evacuation (MIRACLE-S) trial: rationale, design and progress. Cerebrovascular Diseases. https://doi.org/10.1159/ced/accag012
Vancouver
Wang X, Zeng JF, Luo L, Bian H, Liu Z, Xie Z, et al. The minimally invasive soft channel brain hemorrhage evacuation for acute basal ganglia hemorrhage - small hemorrhage evacuation (MIRACLE-S) trial: rationale, design and progress. Cerebrovascular Diseases. 2026. doi:10.1159/ced/accag012
BibTeX
@article{Wang2026,
author = {Wang, Xia and Zeng, Jun-Fa and Luo, Lei and Bian, Hetao and Liu, Zhenchuan and Xie, Zhongxiang and Li, Bing and Zhao, Fuchun and He, Feng and Song, Xiaojie and Chen, Xinghua and Li, Shengjie and Huang, Chuanjiang and Du, Chigang and Wang, Qihao and Song, Lili and Anderson, Craig and Che, Fengyuan and Xin, Tao and Ji, Xunming},
title = {The minimally invasive soft channel brain hemorrhage evacuation for acute basal ganglia hemorrhage - small hemorrhage evacuation (MIRACLE-S) trial: rationale, design and progress},
journal = {Cerebrovascular Diseases},
year = {2026},
doi = {10.1159/ced/accag012}
}
EUVIMED